Amphastar Pharmaceuticals, Inc. (29A.F)
| Previous Close | 36.76 |
| Open | 36.62 |
| Bid | 0.00 x 70000 |
| Ask | 0.00 x 70000 |
| Day's Range | 36.62 - 36.62 |
| 52 Week Range | 35.50 - 59.00 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | 1.848B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | 13.46 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which ...
- ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat ...
- ACCESSWIRE
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for ...
